Janux Therapeutics (NASDAQ:JANX) Stock Gets Price Target Bump from Truist Financial

Posted by Brian Himes on Nov 6th, 2026

Janux Therapeutics (NASDAQ:JANX – Get Free Report) had its target price increased by Truist Financial from $26.00 to $27.00 in a report issued on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. Truist Financial‘s target price would indicate a potential upside of 60.49% from the company’s previous close.

Other equities research analysts have also recently issued reports about the stock. Guggenheim reduced their target price on shares of Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating for the company in a report on Friday, August 7th. TD Cowen raised Janux Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Barclays upped their price objective on shares of Janux Therapeutics from $14.00 to $15.00 and gave the stock an “underweight” rating in a research report on Friday. HC Wainwright restated a “buy” rating on shares of Janux Therapeutics in a research note on Monday, October 19th. Finally, Wolfe Research upgraded shares of Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 price target on the stock in a research note on Monday, August 24th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $36.92.

Check Out Our Latest Research Report on Janux Therapeutics

Janux Therapeutics Trading Up 4.8%

Shares of NASDAQ JANX traded up $0.76 during mid-day trading on Friday, reaching $16.82. The company had a trading volume of 233,773 shares, compared to its average volume of 1,054,173. The firm has a 50 day simple moving average of $17.52 and a two-hundred day simple moving average of $15.39. Janux Therapeutics has a 52-week low of $12.12 and a 52-week high of $35.34. The stock has a market cap of $1.03 billion, a P/E ratio of -10.29 and a beta of 2.44.

Janux Therapeutics (NASDAQ:JANX – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.13. The firm had revenue of $9.29 million for the quarter, compared to analysts’ expectations of $8.03 million. On average, equities analysts expect that Janux Therapeutics will post -1.70 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC boosted its position in shares of Janux Therapeutics by 67.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,642 shares of the company’s stock worth $28,000 after buying an additional 661 shares in the last quarter. Versant Capital Management Inc increased its holdings in Janux Therapeutics by 42.8% during the 2nd quarter. Versant Capital Management Inc now owns 2,615 shares of the company’s stock valued at $40,000 after acquiring an additional 784 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al increased its holdings in Janux Therapeutics by 8.8% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 12,350 shares of the company’s stock valued at $213,000 after acquiring an additional 1,000 shares in the last quarter. Quantinno Capital Management LP raised its position in Janux Therapeutics by 7.6% during the first quarter. Quantinno Capital Management LP now owns 26,064 shares of the company’s stock worth $362,000 after acquiring an additional 1,846 shares during the last quarter. Finally, Fulcrum Asset Management LLP raised its position in Janux Therapeutics by 3,391.2% during the third quarter. Fulcrum Asset Management LLP now owns 2,374 shares of the company’s stock worth $40,000 after acquiring an additional 2,306 shares during the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

(Get Free Report)

Janux Therapeutics, Inc is a clinical-stage biopharmaceutical company developing immune-based medicines for the treatment of cancer and autoimmune diseases. The company’s research is focused on designing therapies that selectively activate the immune system in diseased tissue while limiting activity in healthy tissue.

Janux’s proprietary technology platform is designed to create tumor-activated T-cell engager therapies and other immunomodulators. These medicines are engineered to remain relatively inactive in the circulation and become activated in the tumor microenvironment, with the goal of improving the therapeutic window of immune therapies.